Identification of an optimal mutant allele frequency to detect activating KRAS, NRAS, and BRAF mutations in a commercial cell-free DNA next-generation sequencing assay in colorectal and pancreatic adenocarcinomas

Caughey, BA; Umemoto, K; Green, MF; Ikeda, M; Lowe, ME; Ueno, M; Niedzwiecki, D; Taniguchi, H; Walden, DJ; Komatsu, Y; D'Anna, R; Esaki, T; Denda, T; Datto, MB; Bando, H; Bekaii-Saab, T; Yoshino, T; Strickler, JH; Nakamura, Y

Journal article

Identification of an optimal mutant allele frequency to detect activating KRAS, NRAS, and BRAF mutations in a commercial cell-free DNA next-generation sequencing assay in colorectal and pancreatic adenocarcinomas

Abstract:: Background
Evaluation for activating mutations in KRAS, NRAS, and BRAF in colorectal cancer (CRC) and in KRAS in pancreatic ductal adenocarcinoma (PDAC) is essential for clinical care. Plasma cell-free DNA (cfDNA) next-generation sequencing (NGS) allows convenient assessment of a tumor's molecular profile, however low tumor DNA shedding limits sensitivity. We investigated mutant allele frequency (MAF) of other oncogenic dominant genes to identify a threshold for accurate detection of KRAS, NRAS, and BRAF (RAS/RAF) mutations in cfDNA.
Methods
Molecular and clinical data were obtained from the Duke Molecular Registry of Tumors and the SCRUM-Japan GOZILA study. Patients with CRC or PDAC and a KRAS, NRAS, or BRAF activating single nucleotide variant (SNV) present on tissue NGS and with available cfDNA assays were included. Recursive partitioning and Wilcoxon-rank statistics methods identified potential cut-points for discriminative MAF values.
Results
One hundred and thirty-five CRC and 30 PDAC cases with 198 total cfDNA assays met criteria. Greatest non-RAS/RAF dominant gene MAF of 0.34% provided maximum discrimination for predicting RAS/RAF SNV detection. Sensitivity for RAS/RAF SNVs increased with dominant gene MAF, with MAF ≥1% predicting sensitivity >98%, MAF between 0.34 and 1% predicting sensitivity of 84.0%, and MAF £0.34% predicting sensitivity of 50%. For 43 cfDNA assays that did not detect RAS/RAF SNVs, 18 assays detected 34 other oncogenic variants, of which 80.6% were not also detected on tissue.
Conclusions
Non-RAS/RAF dominant oncogenic mutation MAF ≥1% on cfDNA NGS predicts high sensitivity to detect RAS/RAF oncogenic SNVs in CRC and PDAC. MAF £0.34% indicates an assay may not reliably detect RAS/RAF SNVs, despite detection on tissue testing. Most variants from assays that did not detect RAS/RAF had MAF <1% and were not detected on tissue, suggesting potential confounding. These data suggest a practical approach to determining cfDNA assay adequacy, with implications for guiding clinical decisions in CRC and PDAC.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Caughey, B. A., Umemoto, K., Green, M. F., Ikeda, M., Lowe, M. E., Ueno, M., Niedzwiecki, D., Taniguchi, H., Walden, D. J., Komatsu, Y., D'Anna, R., Esaki, T., Denda, T., Datto, M. B., Bando, H., Bekaii-Saab, T., Yoshino, T., Strickler, J. H., & Nakamura, Y. (2023). Identification of an optimal mutant allele frequency to detect activating KRAS, NRAS, and BRAF mutations in a commercial cell-free DNA next-generation sequencing assay in colorectal and pancreatic adenocarcinomas. Journal of Gastrointestinal Oncology, 14(05), 2083–2096.

MLA Style

Caughey, BA, et al. “Identification of an Optimal Mutant Allele Frequency to Detect Activating KRAS, NRAS, and BRAF Mutations in a Commercial Cell-Free DNA next-Generation Sequencing Assay in Colorectal and Pancreatic Adenocarcinomas.” Journal of Gastrointestinal Oncology, vol. 14, no. 05, 2023, pp. 2083–96.

Chicago Style

Caughey, BA, K Umemoto, MF Green, et al. 2023. “Identification of an Optimal Mutant Allele Frequency to Detect Activating KRAS, NRAS, and BRAF Mutations in a Commercial Cell-Free DNA next-Generation Sequencing Assay in Colorectal and Pancreatic Adenocarcinomas.” Journal of Gastrointestinal Oncology 14 (05): 2083–96.
Print